Despite new immunotherapies aimed at B and T cells, plasma cells and their lifelong antibody secretion constitute a major immune barrier to long‐term graft survival. In this mini‐review, we survey the recent advances that have been made in the biology and immunometabolism of long‐lived plasma cells, and outline aspects of plasma cell function that can be exploited for clinical benefit in recipients of solid organ transplants. A handful of ongoing studies are already targeting plasma cells to achieve desensitization and reduce the alloantibody burden in individuals posttransplant. In reviewing the recent strides made in our understanding of the molecular basis of plasma cell survival, we will place our discussions in the context of existing preclinical and clinical studies. The authors review recent advances in the biology and immunometabolism of plasma cells and outline aspects of plasma cell function that can be exploited for clinical benefit in recipients of solid organ transplants.